<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01651520</url>
  </required_header>
  <id_info>
    <org_study_id>IDRCB 2011-A00836-35</org_study_id>
    <secondary_id>P100126</secondary_id>
    <nct_id>NCT01651520</nct_id>
  </id_info>
  <brief_title>Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis</brief_title>
  <acronym>Flumatep_2</acronym>
  <official_title>Prognosis Value of the Neuronal Damage Detected by Positrons Emission Tomography (PET) With 11C-Flumazenil in Early Multiple Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will use PET and 11C-Flumazenil to visualize and quantify&#xD;
      neuronal injury in the cortex and the deep gray matter of Multiple Sclerosis patients at an&#xD;
      early stage. The investigators will follow up patients to determine the prognostic value of&#xD;
      this neuronal injury.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is now well admitted that multiple sclerosis (MS), which is an inflammatory demyelinating&#xD;
      disease of the central nervous system (CNS) is not restricted to white matter, but also&#xD;
      involves grey matter, either the cortex or the deep grey matter. The progression of grey&#xD;
      matter atrophy measured by MRI during disease course represents an interesting prognosis&#xD;
      marker for long term progression, but this marker lack sensitivity and is hard to interpret&#xD;
      at the individual level.&#xD;
&#xD;
      In the EAE animal models, an early neuronal damage has been described, characterized both by&#xD;
      a synaptic and dendritic loss and by a neuronal apoptosis.&#xD;
&#xD;
      These data strongly suggest that the occurrence of an early neuronal damage during MS course&#xD;
      could represent a major prognosis marker. Therefore there is a crucial need for the&#xD;
      development of imaging techniques, aimed at visualizing and quantifying neuronal damage in&#xD;
      early MS. To date MRI techniques are not able to specifically assess neuronal pathology in&#xD;
      vivo.&#xD;
&#xD;
      In this prospective project we will determine the chronology of appearance and the prognosis&#xD;
      value of the neuronal damage measured by PET with 11C-Flumazenil, concerning further grey&#xD;
      matter atrophy progression and disability progression among a cohort of MS patients with&#xD;
      recent onset.&#xD;
&#xD;
      Four groups of subjects will be included: i) patients with a RRMS evolving since less than 5&#xD;
      years (revised Mc Donald criteria, n=20); ii) patients with a RRMS evolving since more than 5&#xD;
      years and less than 10 years (n=20); iii) patients with a primary progressive MS (PPMS)&#xD;
      evolving since less than 10 years (n=20); iv) Healthy volunteers matched for age and sex (2/3&#xD;
      matched with RRMS patients; 1/3 matched with PPMS patients).&#xD;
&#xD;
      Each subject will pass a neurologic examination, a neuropsychological testing, a first PET&#xD;
      examination with 11C-Flumazenil, a multimodal MRI, with conventional sequences (3DT1, 3D T2&#xD;
      and FLAIR, pre and post contrast T1) and non conventional sequences (MTR, DTI, protonic&#xD;
      spectroscopy).&#xD;
&#xD;
      All patients will be followed prospectively with one visit/year consisting in clinical&#xD;
      neurological, and neuropsychological evaluations as well as multimodal MRI.&#xD;
&#xD;
      For healthy volunteers a second PET 11C-Flumazenil will also be performed to assess&#xD;
      reproducibility and evolution (50% after 1 month, 50% after 1 year).&#xD;
&#xD;
      This study will allow to assess on a larger sample followed prospectively (5 years) the&#xD;
      prognosis value of abnormalities detected and quantified by PET with 11C-Flumazenil on&#xD;
      further grey matter atrophy progression on MRI and disability progression (EDSS, MSFC,&#xD;
      cognitive status). It will also precise the chronology of appearance and the evolution of&#xD;
      neuronal damage in MS, and determine the reproducibility of this technique. Results should&#xD;
      provide a new and more efficient prognosis marker for early MS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>neuronal imaging</measure>
    <time_frame>2 years</time_frame>
    <description>Prognosis value of the neuronal imaging on 2 years evolution (atrophy and EDSS)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Relapsing patients &lt; 5 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relapsing patients &lt; 5 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>relapsing patients &lt; 10 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>relapsing patients &lt; 10 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>primary progressive patients &lt; 10 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>primary progressive patients &lt; 10 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PET with 11C-Flumazenil</intervention_name>
    <description>PET with 11C-Flumazenil.</description>
    <arm_group_label>Relapsing patients &lt; 5 years</arm_group_label>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_label>primary progressive patients &lt; 10 years</arm_group_label>
    <arm_group_label>relapsing patients &lt; 10 years</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Four groups of subjects will be included:&#xD;
&#xD;
          -  patients with a RRMS evolving since less than 5 years (revised Mc Donald criteria,&#xD;
             n=20);&#xD;
&#xD;
          -  patients with a RRMS evolving since more than 5 years and less than 10 years (n=20);&#xD;
&#xD;
          -  patients with a primary progressive MS (PPMS) evolving since less than 10 years&#xD;
             (n=20);&#xD;
&#xD;
          -  Healthy volunteers matched for age and sex (2/3 matched with RRMS patients; 1/3&#xD;
             matched with PPMS patients).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of social insurance&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Age &gt; 55&#xD;
&#xD;
          -  Therapy with benzodiazepine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Stankoff, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pitié Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>July 25, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2012</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurodegeneration</keyword>
  <keyword>Disability</keyword>
  <keyword>Cognition</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flumazenil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

